These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 34280680)

  • 1. Oral administration of methylprednisolone powder for intravenous injection dissolved in water to treat MS and NMOSD relapses during COVID-19 pandemic in a real-world setting.
    Luetic GG; Menichini ML; Fernández Ó
    Mult Scler Relat Disord; 2021 Sep; 54():103148. PubMed ID: 34280680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of central nervous system demyelinating diseases during the coronavirus disease 2019 pandemic: a practical approach.
    ApÓstolos-Pereira SL; Silva GD; Disserol CCD; Feo LB; Matos AMB; Schoeps VA; Gomes ABAGR; Boaventura M; Mendes MF; Callegaro D
    Arq Neuropsiquiatr; 2020 Jul; 78(7):430-439. PubMed ID: 32609290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple sclerosis, neuromyelitis optica spectrum disorder and COVID-19: A pandemic year in Czechia.
    Stastna D; Menkyova I; Drahota J; Mazouchova A; Adamkova J; Ampapa R; Grunermelova M; Peterka M; Recmanova E; Rockova P; Rous M; Stetkarova I; Valis M; Vachova M; Woznicova I; Horakova D
    Mult Scler Relat Disord; 2021 Sep; 54():103104. PubMed ID: 34216998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relapses after SARS-CoV-2 vaccination in patients with neuromyelitis optica spectrum disorder and multiple sclerosis.
    Kong L; Wang X; Chen H; Shi Z; Lang Y; Zhang Y; Zhou H
    Mult Scler Relat Disord; 2022 Dec; 68():104167. PubMed ID: 36170773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Would it be recommended treating multiple sclerosis relapses with high dose oral instead intravenous steroids during the COVID-19 pandemic? Yes.
    Segamarchi C; Silva B; Saidon P; Garcea O; Alonso R
    Mult Scler Relat Disord; 2020 Nov; 46():102449. PubMed ID: 32853893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral versus intravenous methylprednisolone for the treatment of multiple sclerosis relapses: A meta-analysis of randomized controlled trials.
    Liu S; Liu X; Chen S; Xiao Y; Zhuang W
    PLoS One; 2017; 12(11):e0188644. PubMed ID: 29176905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis.
    Burton JM; O'Connor PW; Hohol M; Beyene J
    Cochrane Database Syst Rev; 2012 Dec; 12():CD006921. PubMed ID: 23235634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose oral methylprednisolone for the treatment of multiple sclerosis relapses: cost-minimisation analysis and patient's satisfaction.
    Horta-Hernández AM; Esaclera-Izquierdo B; Yusta-Izquierdo A; Martín-Alcalde E; Blanco-Crespo M; Álvarez-Nonay A; Torralba M
    Eur J Hosp Pharm; 2019 Sep; 26(5):280-284. PubMed ID: 31656616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Features of COVID-19 on Patients With Neuromyelitis Optica Spectrum Disorders.
    Apostolos-Pereira SL; Campos Ferreira L; Boaventura M; de Carvalho Sousa NA; Joca Martins G; d'Almeida JA; Pitombeira M; Silvestre Mendes L; Fukuda T; Souza Cabeça HL; Chaves Rocha L; Santos de Oliveira B; Vieira Stella CR; Lobato de Oliveira EM; de Souza Amorim L; Ferrari de Castro A; Pereira Gomes Neto A; Diogo Silva G; Bueno L; de Morais Machado M; Castello Dias-Carneiro R; Maciel Dias R; Porto Moreira A; Piccolo A; Kuntz Grzesiuk A; Muniz A; Diniz Disserol C; Ferreira Vasconcelos C; Kaimen-Maciel D; Sisterolli Diniz D; Comini-Frota E; Coronetti Rocha F; Cruz Dos Santos GA; Dadalti Fragoso Y; Sciascia do Olival G; Ruocco HH; Siqueira HH; Sato HK; Figueiredo JA; Cortoni Calia L; Teixeira Dourado ME; Scolari L; Ribeiro Soares Neto H; Melges L; Magno Gonçalves MV; Vellutini Pimentel ML; de Castro Ribeiro M; Gurrola Arambula O; Diniz da Gama P; Leite Menon R; Barbosa Thomaz R; de Rizo Morales R; Sobreira S; Machado SN; Gonsalves Jubé Ribeiro T; Coelho Santa Rita Pereira V; Maia Costa V; da Nóbrega Junior AW; Vieira Alves-Leon S; Mamprim de Morais Perin M; Donadi E; Adoni T; Gomes S; Brito Ferreira M; Callegaro D; Mendes MF; Brum D; von Glehn F;
    Neurol Neuroimmunol Neuroinflamm; 2021 Nov; 8(6):. PubMed ID: 34446434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pediatric-onset multiple sclerosis in Brazilian patients: Clinical features, treatment response and comparison to pediatric neuromyelitis optica spectrum disorders.
    Fragomeni MO; Bichuetti DB; Oliveira EML
    Mult Scler Relat Disord; 2018 Oct; 25():138-142. PubMed ID: 30075406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders.
    Fan M; Qiu W; Bu B; Xu Y; Yang H; Huang D; Lau AY; Guo J; Zhang MN; Zhang X; Yang CS; Chen J; Zheng P; Liu Q; Zhang C; Shi FD
    Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32503092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19 in multiple sclerosis and neuromyelitis optica spectrum disorder patients in Latin America: COVID-19 in MS and NMOSD patients in LATAM.
    Alonso R; Silva B; Garcea O; Diaz PEC; Dos Passos GR; Navarro DAR; Valle LAG; Salinas LCR; Negrotto L; Luetic G; Tkachuk VA; Míguez J; de Bedoya FHD; Goiry LG; Sánchez NER; Burgos M; Steinberg J; Balbuena ME; Alvarez PM; López PA; Ysrraelit MC; León RA; Cohen AB; Gracia F; Molina O; Casas M; Deri NH; Pappolla A; Patrucco L; Cristiano E; Tavolini D; Nadur D; Granda AMT; Weiser R; Cassará FP; Sinay V; Rodríguez CC; Lazaro LG; Menichini ML; Piedrabuena R; Escobar GO; Carrá A; Chertcoff A; Pujols BS; Vrech C; Tarulla A; Carvajal R; Mainella C; Becker J; Peeters LM; Walton C; Serena MA; Nuñez S; Rojas JI
    Mult Scler Relat Disord; 2021 Jun; 51():102886. PubMed ID: 33744758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of intravenous methylprednisolone pulse therapy in patients with multiple sclerosis and neuromyelitis optica.
    Yamasaki R; Matsushita T; Fukazawa T; Yokoyama K; Fujihara K; Ogino M; Yokota T; Miyamoto K; Niino M; Nomura K; Tomioka R; Tanaka M; Kawachi I; Ohashi T; Kaida K; Matsui M; Nakatsuji Y; Ochi H; Fukaura H; Kanda T; Nagaishi A; Togo K; Mizusawa H; Murai H; Kira J
    Mult Scler; 2016 Sep; 22(10):1337-48. PubMed ID: 26564994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis.
    Barnes D; Hughes RA; Morris RW; Wade-Jones O; Brown P; Britton T; Francis DA; Perkin GD; Rudge P; Swash M; Katifi H; Farmer S; Frankel J
    Lancet; 1997 Mar; 349(9056):902-6. PubMed ID: 9093250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experience of South American MS and/or NMOSD experts in practice during the COVID-19 pandemic: Focus on Telemedicine.
    Alonso R; Carvajal R; Boaventura M; Galleguillos L
    Mult Scler Relat Disord; 2021 Feb; 48():102702. PubMed ID: 33360914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical characteristics and follow-up of pediatric patients with neuromyelitis optica and neuromyelitis optica spectrum disorders].
    Yun W; Weihua Z; Xiaotun R; Jiuwei L; Xinying Y; Junlan L; Changhong D; Chunhong C; Haitao R; Liying C; Fang F
    Zhonghua Er Ke Za Zhi; 2015 Apr; 53(4):268-73. PubMed ID: 26182501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS.
    Ramo-Tello C; Grau-López L; Tintoré M; Rovira A; Ramió i Torrenta L; Brieva L; Cano A; Carmona O; Saiz A; Torres F; Giner P; Nos C; Massuet A; Montalbán X; Martínez-Cáceres E; Costa J
    Mult Scler; 2014 May; 20(6):717-25. PubMed ID: 24144876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Home administration of intravenous methylprednisolone for multiple sclerosis relapses: the experience of French multiple sclerosis networks.
    Créange A; Debouverie M; Jaillon-Rivière V; Taithe F; Liban D; Moutereau A; Clavelou P; Defer G
    Mult Scler; 2009 Sep; 15(9):1085-91. PubMed ID: 19556312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in patient and physician attitudes resulting from COVID-19 in neuromyelitis optica spectrum disorder and multiple sclerosis.
    Salama S; Giovannoni G; Hawkes CH; Lechner-Scott J; Waubant E; Levy M
    Mult Scler Relat Disord; 2020 Jul; 42():102259. PubMed ID: 32571580
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.